NO20064193L - fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser - Google Patents

fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser

Info

Publication number
NO20064193L
NO20064193L NO20064193A NO20064193A NO20064193L NO 20064193 L NO20064193 L NO 20064193L NO 20064193 A NO20064193 A NO 20064193A NO 20064193 A NO20064193 A NO 20064193A NO 20064193 L NO20064193 L NO 20064193L
Authority
NO
Norway
Prior art keywords
cytokine activity
modulating cytokine
related reagents
methods
modulating
Prior art date
Application number
NO20064193A
Other languages
English (en)
Inventor
Robert A Kastelein
Jochen Schmitz
Martin Oft
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064193(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20064193L publication Critical patent/NO20064193L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Sammendrag Tilveiebrakt blir fremgangsmåter for modulering av cytokinaktivitet, f.eks. med det formålet å behandle immunforstyrrelser og inflammatoriske forstyrrelser, inkludert tumorer og kreft. Også tilveiebrakt er fremgangsmåter for administrering av agonister eller antagonister av IL-33 og IL-33reseptor
NO20064193A 2004-02-17 2006-09-15 fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser NO20064193L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54573004P 2004-02-17 2004-02-17
PCT/US2005/004743 WO2005079844A2 (en) 2004-02-17 2005-02-15 Use for interleukin-33 (il33) and the il-33 receptor complex

Publications (1)

Publication Number Publication Date
NO20064193L true NO20064193L (no) 2006-11-16

Family

ID=34886190

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064193A NO20064193L (no) 2004-02-17 2006-09-15 fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser

Country Status (14)

Country Link
US (5) US20050203046A1 (no)
EP (2) EP1725261B1 (no)
JP (4) JP4949859B2 (no)
CN (1) CN1917902A (no)
AT (1) ATE496636T1 (no)
AU (1) AU2005215528B2 (no)
BR (1) BRPI0507808A (no)
CA (1) CA2555236C (no)
DE (1) DE602005026105D1 (no)
NO (1) NO20064193L (no)
NZ (1) NZ549040A (no)
TW (2) TW201304802A (no)
WO (1) WO2005079844A2 (no)
ZA (1) ZA200606844B (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
EP3072978B1 (en) 2002-05-09 2018-07-11 The Brigham and Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2009511572A (ja) * 2005-10-16 2009-03-19 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 炎症性皮膚疾患、障害または症状のための医薬組成物および診断方法
ES2351623T3 (es) * 2006-04-24 2011-02-08 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de una enfermedad grave.
US20090305265A1 (en) * 2006-04-27 2009-12-10 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PT2021796E (pt) 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
HUE025058T2 (en) * 2006-05-02 2016-01-28 Critical Care Diagnostics Inc Differential diagnosis of pulmonary and cardiovascular disease
WO2007130627A2 (en) * 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
SE532250C2 (sv) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av IL-33 för behandling av inflammatoriska tillstånd med en stark TH2 komponent genom vaccinering
WO2008132709A1 (en) * 2007-04-26 2008-11-06 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Products for altering il-33 activity and methods therefor
JP2010527936A (ja) * 2007-05-18 2010-08-19 メディミューン，エルエルシー 炎症性疾患におけるｉｌ−３３
DK2827152T3 (en) 2008-04-18 2016-09-12 Critical Care Diagnostics Inc PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS
JP5539660B2 (ja) * 2009-03-10 2014-07-02 公益財団法人ヒューマンサイエンス振興財団 粘膜ワクチン用アジュバント
ES2655079T3 (es) * 2009-09-10 2018-02-16 Merck Sharp & Dohme Corp. Uso de antagonistas de IL-33 para tratar enfermedades fibróticas
CA2824500C (en) * 2011-02-23 2020-02-25 Georg Fertig Antibodies against human il33r and uses thereof
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
EP3605104B1 (en) 2011-03-17 2021-09-15 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
CN104737170A (zh) 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
WO2014090800A1 (en) * 2012-12-10 2014-06-19 Vib Vzw Novel interleukin-33 inhibitors
KR101780575B1 (ko) * 2013-02-14 2017-09-21 건국대학교 산학협력단 신규한 인터루킨-33 수용체와 결합 단백질 조성물 및 그 용도
EP2958583B1 (en) * 2013-02-22 2018-04-11 Magic Epoch Holdings Limited Il-33 and treatment of neurodegenerative diseases
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
CA2904377C (en) * 2013-03-15 2021-07-13 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
EP3782628B1 (en) * 2013-03-15 2024-08-07 Elixirgen Therapeutics, Inc. Methods of using zscan4 for rejuvenating human cells
WO2015042521A1 (en) 2013-09-20 2015-03-26 University Of Virginia Patent Foundation Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
CN111012905B (zh) * 2013-10-07 2023-12-22 宾夕法尼亚大学理事会 具有作为佐剂的白介素-33的疫苗
FI3088517T3 (fi) * 2013-12-26 2023-11-30 Mitsubishi Tanabe Pharma Corp Ihmisen Anti-IL-33 neutraloiva monoklonaalinen vasta-aine
EP3092253B1 (en) 2014-01-10 2021-03-17 AnaptysBio, Inc. Antibodies directed against interleukin-33 (il-33)
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
JP7231326B2 (ja) * 2014-11-10 2023-03-01 ジェネンテック， インコーポレイテッド Ｉｌ－３３媒介性障害のための治療及び診断方法
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
EP3265107B1 (en) 2015-03-02 2024-10-02 180 Therapeutics LP Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
EP3265114A4 (en) * 2015-03-03 2019-11-13 Jefferies, Wilfred MODULATION OF ANTICANCER IMMUNITY USING INNED TYPE 2 LYMPHOID CELLS, INTERLEUKIN 33 AND / OR INTERFERON-INDUCED PROTEIN 44
WO2016156440A1 (en) 2015-03-31 2016-10-06 Medimmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
JP6501650B2 (ja) * 2015-06-25 2019-04-17 田辺三菱製薬株式会社 ヒト抗ｉｌ−３３中和モノクローナル抗体
US10813979B2 (en) * 2015-07-10 2020-10-27 The Hong Kong University Of Science And Technology Methods and compositions for treating neurodegenerative and neuroinflammatory conditions
AU2016333903B2 (en) * 2015-10-06 2021-07-08 Regeneron Pharmaceuticals, Inc. Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof
KR101765397B1 (ko) 2015-12-02 2017-08-07 한국과학기술원 질점막을 통한 바이러스 감염 취약 진단 마커로서의 il-33의 용도
CN109415436A (zh) 2016-04-27 2019-03-01 辉瑞公司 抗il-33抗体及其组合物、方法及用途
SG10202100100UA (en) 2016-06-29 2021-02-25 Checkpoint Therapeutics Inc Pd-l1-specific antibodies and methods of using the same
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
JP6995127B2 (ja) 2017-02-10 2022-02-04 ジェネンテック， インコーポレイテッド 抗トリプターゼ抗体、その組成物、及びその使用
CN110573174A (zh) * 2017-02-17 2019-12-13 通用医疗公司 用于治疗脑损伤的方法和组合物
EP3610041A1 (en) 2017-04-13 2020-02-19 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
WO2018204848A1 (en) 2017-05-05 2018-11-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Ocular applications of matrix bound vesicles (mbvs)
WO2019045075A1 (ja) 2017-08-31 2019-03-07 田辺三菱製薬株式会社 Ｉｌ－３３アンタゴニストを含む子宮内膜症治療剤
JP7418337B2 (ja) 2018-02-09 2024-01-19 ジェネンテック， インコーポレイテッド マスト細胞媒介性炎症性疾患の治療法及び診断法
IL277890B2 (en) 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantification of IL-33
CN112805016A (zh) * 2018-05-03 2021-05-14 联邦高等教育系统匹兹堡大学 包含il-33的基质结合囊泡(mbv)及其用途
US11730762B2 (en) 2018-08-30 2023-08-22 HCW Biologics, Inc. Methods for stimulating proliferation or differentiation of an immune cell with a multi-chain chimeric polypeptide
AU2019328313A1 (en) 2018-08-30 2021-02-25 Immunitybio, Inc. Single-chain chimeric polypeptides and uses thereof
AU2019328290B2 (en) 2018-08-30 2024-10-10 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
TW202102260A (zh) 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物
EP3987010A1 (en) 2019-06-21 2022-04-27 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3145250A1 (en) * 2019-06-30 2021-01-07 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of pancreatic cancer
CN114555109A (zh) * 2019-10-11 2022-05-27 交晨生物医药技术(上海)有限公司 使用il-33蛋白治疗癌症的方法
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Antibodies against interleukin-33 and uses thereof
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247604A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
CN112210556A (zh) * 2020-10-15 2021-01-12 扬州大学 一组靶向干扰IL-33表达的shRNA、重组腺病毒载体及其构建方法和应用
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN114426981B (zh) * 2022-02-21 2022-11-29 吉林农业大学 非洲猪瘟病毒抗原蛋白重组表达载体、重组植物乳酸菌及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
WO1992010210A1 (en) * 1990-12-14 1992-06-25 E.I. Du Pont De Nemours And Company Inhibition of angiogenesis by il-1
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US5576191A (en) * 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
AU6501296A (en) 1995-07-21 1997-02-18 General Hospital Corporation, The Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
ATE406441T1 (de) 1997-10-29 2008-09-15 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
JP2001526892A (ja) * 1997-12-23 2001-12-25 イミュネックス・コーポレーション Ｓｉｇｉｒｒｄｎａおよびポリペプチド
GB9727172D0 (en) * 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
EP1110969A4 (en) 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18 BINDING PROTEIN
AU764211C (en) 1998-12-01 2006-03-30 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001046697A2 (en) 1999-12-21 2001-06-28 Millennium Predictive Medicine Identification, assessment, prevention, and therapy of breast cancer
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
AU2002226079A1 (en) 2000-12-08 2002-06-18 Curagen Corporation Method of detecting and treating tuberous sclerosis complex associated disorders
US20040009481A1 (en) * 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
EP1478772A2 (en) 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
AU2001289843A1 (en) 2001-08-28 2002-02-13 Bayer Cropscience Ag Polypeptides for identifying herbicidally active compounds
WO2004056868A2 (en) * 2002-12-19 2004-07-08 Endocube Sas Nf-hev compositions and methods of use
WO2005067667A2 (en) 2004-01-07 2005-07-28 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
JP2010527936A (ja) 2007-05-18 2010-08-19 メディミューン，エルエルシー 炎症性疾患におけるｉｌ−３３

Also Published As

Publication number Publication date
CN1917902A (zh) 2007-02-21
CA2555236C (en) 2015-05-05
WO2005079844A3 (en) 2005-11-24
TWI372628B (en) 2012-09-21
ZA200606844B (en) 2008-05-28
ATE496636T1 (de) 2011-02-15
EP2283860A2 (en) 2011-02-16
NZ549040A (en) 2009-07-31
US9970944B2 (en) 2018-05-15
TW200539891A (en) 2005-12-16
JP4949859B2 (ja) 2012-06-13
US20090041718A1 (en) 2009-02-12
US20140140954A1 (en) 2014-05-22
US20180128837A1 (en) 2018-05-10
AU2005215528A1 (en) 2005-09-01
JP2007523089A (ja) 2007-08-16
EP2283860A3 (en) 2013-06-05
WO2005079844A2 (en) 2005-09-01
JP2014098026A (ja) 2014-05-29
CA2555236A1 (en) 2005-09-01
US20050203046A1 (en) 2005-09-15
US20070160579A1 (en) 2007-07-12
TW201304802A (zh) 2013-02-01
BRPI0507808A (pt) 2007-07-10
JP2011178810A (ja) 2011-09-15
EP1725261B1 (en) 2011-01-26
AU2005215528B2 (en) 2009-04-30
JP2016034948A (ja) 2016-03-17
EP1725261A2 (en) 2006-11-29
DE602005026105D1 (de) 2011-03-10

Similar Documents

Publication Publication Date Title
NO20064193L (no) fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser
TW200531679A (en) Methods of modulating cytokine activity; related reagents
NO20064194L (no) Fremgangsmate for a modulere IL-23-aktivitet, beslektede reagenser
NO20054630D0 (no) Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser
CY1120257T1 (el) ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΜΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ JANUS
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
CY1109521T1 (el) Μεθοδοι ρυθμισης υποδοχεων cd200
DK1771474T3 (da) Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
AR064458A1 (es) Antagonistas especificos de vegf para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadios tempranos
CY1108645T1 (el) Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη
WO2008137838A3 (en) Interferon alpha-induced pharmacodynamic markers
EP1589998A4 (en) USES OF MAMMALIAN CYTOKINE AND RELATED REAGENTS
ATE534902T1 (de) Replikationsproteinn ciz1
ATE451393T1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
WO2005010148A3 (en) Marks as modifiers of the pten pathway and methods of use
WO2005060998A3 (en) Methods of modulating cytokine activity; related reagents
ITMO20040139A1 (it) Metodo ed apparato per la produzione di conglomerati da costruzione,particolarmente conglomerati bituminosi,misto cementato,calcestruzzo o simili.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP, US

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY

FC2A Withdrawal, rejection or dismissal of laid open patent application